BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Art Pappas will participate on a panel at the C21 BioVentures Conference in Napa, Ca titled "Structured Acquisitions: Win-Win or Lose-Lose?"
News | 04. 08. 2009
